Brachytherapy has been shown to be a safe and effective globe-conserving therapy for
uveal melanoma. At the current standard dose of 85 Gy, modeled after the Collaborative
Ocular Melanoma Study (COMS) trials, brachytherapy is associated with high rates of
radiation-related complications.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Advances in Ophthalmology and OptometryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Ocular melanoma: an overview of the current status.Int J Clin Exp Pathol. 2013; 6: 1230-1244
- Uveal melanoma: trends in incidence, treatment, and survival.Ophthalmology. 2011; 118: 1881-1885
- The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society.Cancer. 1998; 83: 1664-1678
- Incidence of noncutaneous melanomas in the U.S.Cancer. 2005; 103: 1000-1007
- MD RHRJ Ophthalmology AA of. 2014-2015 Basic and clinical science course (BCSC): section 4: ophthalmic pathology and intraocular tumors. American Academy of Ophthalmology, 2014
- Management of posterior uveal melanoma: past, present, and future: the 2014 Charles L. Schepens lecture.Ophthalmology. 2015; 122: 414-428
- Malignant melanoma of the choroid treated with radioactive applicators: Hunterian lecture delivered at the Royal College of Surgeons of England on 29th November 1960.Ann R Coll Surg Engl. 1961; 29: 170-182
- The American Brachytherapy Society recommendations for brachytherapy of uveal melanomas.Int J Radiat Oncol Biol Phys. 2003; 56: 544-555
- The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report no. 19.Ophthalmology. 2002; 109: 2197-2206
- The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28.Arch Ophthalmol. 2006; 124: 1684-1693
- Intraoperative ultrasonography-guided positioning of iodine 125 plaque brachytherapy in the treatment of choroidal melanoma.Ophthalmology. 2012; 119: 1073-1077
- Episcleral brachytherapy of uveal melanoma: role of intraoperative echographic confirmation.Br J Ophthalmol. 2017; 101: 747-751
- Outcomes of choroidal melanomas treated with eye physics: a 20-year review.JAMA Ophthalmol. 2013; 131: 1435-1442
- Use of the toric surgical marker to aid in intraoperative plaque placement for the USC eye physics plaques to treat uveal melanoma: a new surgical technique.Ophthalmic Surg Lasers Imaging Retina. 2015; 46: 866-870
- Fine-needle aspiration biopsy of uveal melanoma: outcomes and complications.Br J Ophthalmol. 2016; 100: 456-462
- Multi-year follow-up of fine-needle aspiration biopsy in choroidal melanoma.Ophthalmology. 2012; 119: 606-610
- A prognostic test to predict the risk of metastasis in uveal melanoma based on a 15-gene expression profile.Methods Mol Biol. 2014; 1102: 427-440
- Dosimetry of (125)I and (103)Pd COMS eye plaques for intraocular tumors: report of Task Group 129 by the AAPM and ABS.Med Phys. 2012; 39: 6161-6184
- Finger’s “slotted” eye plaque for radiation therapy: treatment of juxtapapillary and circumpapillary intraocular tumours.Br J Ophthalmol. 2007; 91: 891-894
- Iodine-125 brachytherapy for uveal melanoma: a systematic review of radiation dose.Ocul Oncol Pathol. 2017; 3: 193-198
- Pattern of local recurrence after I-125 episcleral brachytherapy for uveal melanoma in a Spanish referral ocular oncology unit.Am J Ophthalmol. 2017; 180: 39-45
- Local recurrence significantly increases the risk of metastatic uveal melanoma.Ophthalmology. 2016; 123: 86-91
- Local treatment failure after globe-conserving therapy for choroidal melanoma.Br J Ophthalmol. 2013; 97: 804-811
- Ocular complications following I-125 brachytherapy for choroidal melanoma.Eye (Lond). 2009; 23: 1254-1268
- Uveal melanoma treated with iodine-125 episcleral plaque: an analysis of dose on disease control and visual outcomes.Int J Radiat Oncol Biol Phys. 2014; 89: 127-136
- (103)Pd versus (125)I ophthalmic plaque brachytherapy: preoperative comparative radiation dosimetry for 319 uveal melanomas.J Radiat Oncol. 2014; 3: 409-416
- Dosimetric comparison of 106Ru and 125I plaques for treatment of shallow (< or =5 mm) choroidal melanoma lesions.Br J Radiol. 2008; 81: 784-789
- Ruthenium-106 brachytherapy for thick uveal melanoma: reappraisal of apex and base dose radiation and dose rate.J Contemp Brachytherapy. 2016; 8: 66-73
- Outcomes of medium choroidal melanomas treated with ruthenium brachytherapy guided by three-dimensional pretreatment modeling.Brachytherapy. 2015; 14: 718-725
- Selection of iodine 125 for the collaborative ocular melanoma study.Arch Ophthalmol. 1987; 105: 763-764
- Attenuation of iodine 125 radiation with vitreous substitutes in the treatment of uveal melanoma.Arch Ophthalmol. 2010; 128: 888-893
Eye physics. Available at: http://www.eyephysics.com/. Accessed December 20, 2017.
- Conformal episcleral plaque therapy.Int J Radiat Oncol Biol Phys. 1997; 39: 505-519
- Improved treatment planning for COMS eye plaques.Int J Radiat Oncol Biol Phys. 2005; 61: 1227-1242
- The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma.Brachytherapy. 2014; 13: 1-14
- Treatment of choroidal melanoma with I-125 plaque.Int J Radiat Oncol Biol Phys. 1993; 26: 619-623
- Alternative dose for choroidal melanoma treated with an iodine-125 radioactive plaque: a single-institution retrospective study.Int J Radiat Oncol Biol Phys. 2010; 78: 844-848
- Local failure after episcleral brachytherapy for posterior uveal melanoma: patterns, risk factors, and management.Am J Ophthalmol. 2017; 177: 9-16
- Prescribing to tumor apex in episcleral plaque iodine-125 brachytherapy for medium-sized choroidal melanoma: a single-institutional retrospective review.Brachytherapy. 2015; 14: 726-733
- Ruthenium-106 plaque brachytherapy for thick posterior uveal melanomas.Br J Ophthalmol. 2009; 93: 1167-1171
- Plaque radiotherapy for large posterior uveal melanomas (> or =8-mm thick) in 354 consecutive patients.Ophthalmology. 2002; 109: 1838-1849
- Comparison of episcleral plaque and proton beam radiation therapy for the treatment of choroidal melanoma.Ophthalmology. 1999; 106: 1579-1587
- A new way in the conservative therapy of intraocular tumors by means of beta-irradiation (Ruthenium 106) with preservation of vision.Klin Monatsbl Augenheilkd. 1966; 148 ([in German]): 682-699
- Posterior uveal melanoma treated with I-125 brachytherapy or primary enucleation.Eye Lond. 2008; 22: 1398-1403
- Outcomes of iodine-125 plaque brachytherapy for uveal melanoma with intraoperative ultrasonography and supplemental transpupillary thermotherapy.Int J Radiat Oncol Biol Phys. 2014; 88: 801-805
- Radiation complications and tumor control after 125I plaque brachytherapy for ocular melanoma.Int J Radiat Oncol Biol Phys. 2005; 63: 101-108
- Dose de-escalation with gamma knife radiosurgery in the treatment of choroidal melanoma.Int J Radiat Oncol Biol Phys. 2009; 75: 170-176
- Dosimetric and radiobiologic comparison of 103Pd COMS plaque brachytherapy and Gamma Knife radiosurgery for choroidal melanoma.Brachytherapy. 2017; 16: 433-443
- A randomized controlled trial of varying radiation doses in the treatment of choroidal melanoma.Arch Ophthalmol. 2000; 118: 773-778
- Proton beam irradiation of uveal melanomas. Results of 5 1/2-year study.Arch Ophthalmol Chic Ill 1960. 1982; 100: 928-934
- Ophthalmic and adnexal complications of radiotherapy.Acta Ophthalmol Scand. 2007; 85: 240-250
- Risk factors for radiation maculopathy after ophthalmic plaque radiation for choroidal melanoma.Am J Ophthalmol. 2010; 149: 608-615
- Effect of radiation dose on ocular complications after iodine brachytherapy for large uveal melanoma: empirical data and simulation of collimating plaques.Invest Ophthalmol Vis Sci. 2004; 45: 3425-3434
- Radiation dose-volume effects of optic nerves and chiasm.Int J Radiat Oncol Biol Phys. 2010; 76: S28-S35
- Posttreatment visual acuity in patients treated with episcleral plaque therapy for choroidal melanomas: dose and dose rate effects.Int J Radiat Oncol Biol Phys. 2002; 52: 989-995
- New Zealand experience of I125 brachytherapy for choroidal melanoma.Clin Exp Ophthalmol. 2005; 33: 490-494
- Risk factors for cataract after palladium-103 ophthalmic plaque radiation therapy.Int J Radiat Oncol Biol Phys. 2011; 80: 800-806
- Tumour location affects the incidence of cataract and retinopathy after ophthalmic plaque radiation therapy.Br J Ophthalmol. 2000; 84: 1068-1070
Article info
Publication history
Published online: May 22, 2018
Footnotes
Disclosure Statement: The authors have nothing to disclose.
Identification
Copyright
© 2018 Elsevier Inc. All rights reserved.
